The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
I don't have much time to search emails, contact details etc etc but if someone already has this info, happy to share it, then i'm happy to bash out a few emails expressing my concerns etc etc. Thanks
Twonko
Was going to post something similar.......always seems 1 step forward 2 steps back.....think it's time to move out
It's all talk and no action.....they'll be presenting at seminars etc etc for the next friggin 15 years.
Already written this investment off, actions speak louder than words.
I see GSK mention this in their 3rd Quarter Results today....As an investor there too i'm delighted results are very good, however what impact will this have with SNG ? It's all gone very quiet !!!
"On Wednesday, GSK said it had secured priority regulatory review in the United States for its RSV vaccine, with a decision expected by early May"
"GSK is among a handful of drugmakers racing to develop a vaccine for the respiratory virus, which causes thousands of hospitalisations and deaths each year"
If approved, the shots are expected to generate billions in sales for their makers, given the complex molecular structure of the virus and safety concerns have stymied protracted efforts to develop a vaccine.
Next dividend is 12 Jan..........it's ex dividend date in a couple of weeks.
Nice to see the rise and hopefully back to where we should be.
So are we pinning our hopes on a 10 min presentation ?? If so god help us !!
Yep, Ma Turd i'm afraid.
With my 291p buy on Thursday :)
A respiratory jab ! Affect us in any way ?
Issued: 13 October 2022, London UK
GSK's older adult respiratory syncytial virus (RSV) vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6% in pivotal trial.
· Data to be presented at IDWeek 2022 showed overall vaccine efficacy against RSV-lower respiratory tract disease (LRTD) in adults aged 60 years and above, with a favourable safety profile
· Consistent high vaccine efficacy observed against LRTD in severe disease (94.1%), adults aged 70-79 years (93.8%) and in adults with underlying comorbidities (94.6%)
Sativa,
Believe me there's no fun being invested here at this moment in time !
Why , whose coming to our rescue in this debacle !!
This isn't a buy then at the moment ?
Sativa,
You mean the two x 1 million ( not 100k )
Anyone know what their ave is roughly now .......... I know mine is 96p :(((
so they are still increasing.
Nothing this month.......expecting more wins from next month having added and now have max allowed.
The results from the second phase clinical trial for the treatment, known as SNG001, revealed a non-significant but "encouraging" 86% relative risk reduction among 220 patients, said Synairgen's boss, Richard Marsden.
Anyone care to elaborate ?
An uneducated guess, however feel nothings going to happen now until next year. Prepare for the worst, but hoping for the best.
Time to top up or not.....?? Seems a good price at the moment or worth waiting a bit longer ????
Yet another stock that i've picked which has turned to s..te !!!
It's a cluster ****, they simply don't have a clue in what they are doing.